Shots:
- Inocras and AimedBio have partnered to integrate Inocras’ whole-genome sequencing (WGS) platform into AimedBio’s ADC clinical programs, alongside AimedBio’s strategic equity investment in Inocras
- As per the deal, AimedBio will use Inocras’ WGS, cancer intelligence platform, & multi-omics analyses across its ADC trials to enable biomarker discovery, patient selection, and novel target identification
- The collaboration aims to accelerate clinical development, enable precision drug discovery, and explore global commercial opportunities by integrating AimedBio’s drug screening with Inocras’ diagnostic platform
Ref: Businesswire | Image: Inocras & AimedBio | Press Release
Related News: Junshi Biosciences Licenses Roconkibart to Fosun Wanbang in Greater China
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
